FY2029 Earnings Estimate for ABVX Issued By Leerink Partnrs

ABIVAX Société Anonyme (NASDAQ:ABVX) – Analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of ABIVAX Société Anonyme in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($0.17) per share for the year. The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.92) per share.

Other equities research analysts also recently issued reports about the stock. Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, ABIVAX Société Anonyme presently has a consensus rating of “Buy” and a consensus target price of $38.67.

ABIVAX Société Anonyme Price Performance

NASDAQ ABVX opened at $5.85 on Thursday. ABIVAX Société Anonyme has a 52 week low of $5.49 and a 52 week high of $17.02. The stock has a fifty day moving average of $7.13 and a 200-day moving average of $9.55.

Institutional Trading of ABIVAX Société Anonyme

A number of hedge funds have recently modified their holdings of ABVX. abrdn plc raised its holdings in ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after acquiring an additional 198,225 shares during the period. BNP Paribas Financial Markets grew its position in shares of ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the last quarter. Walleye Capital LLC increased its stake in shares of ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after purchasing an additional 80,807 shares during the period. Point72 Asset Management L.P. lifted its holdings in ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after purchasing an additional 119,300 shares during the last quarter. Finally, GAMMA Investing LLC bought a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.